Artigos em foco neste episódio:
#2 – Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial DOI: 10.1056/NEJMoa2509688
#3 – Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial DOI: 10.1016/S0140-6736(25)02155-5
